Pfizer Questions Future Investments in Germany Over Proposed Drug Price Caps

Pfizer's CEO Albert Bourla has raised concerns over Germany's proposed healthcare cost-cutting measures, leading the company to review its planned investments in the country. The pharmaceutical industry fears these changes may undermine investment predictability. Similar reactions have been seen from other drugmakers, such as Eli Lilly and Boehringer Ingelheim.

Pfizer is reevaluating its planned investments in Germany due to concerns over new government proposals to limit drug pricing, CEO Albert Bourla communicated to Chancellor Friedrich Merz. This move marks another instance of pharmaceutical companies reacting to these policy changes, following similar actions by Eli Lilly and Boehringer Ingelheim.

The letter from Bourla highlighted uncertainties affecting the pharmaceutical industry's long-term strategic decisions. While Pfizer did not detail which investments might be affected, the sentiment echoes wider industry fears about the implications of proposed cost-containment measures in Germany's healthcare system.

Germany's legislative proposal to cap health insurance costs has positioned the country as a critical battleground in ongoing negotiations between drug companies and European governments. The tension grows from an international context, including U.S. pricing strategies, as companies like Pfizer seek conditions conducive to launching new medicines in Europe's market.